Management

Guy DiPierro

Guy DiPierro, CEO and Founder. Mr. DiPierro has extensive experience regarding strategic technology collaborations and the incubation of technology driven companies. Mr. DiPierro served as Executive Vice President of a global venture capital fund and strategic network aggregator, where he was primarily responsible for developing and incubating start-up technology companies. Mr. DiPierro has extensive experience regarding business strategy, joint ventures and strategic collaborations, M&A and licensing transactions. Mr. DiPierro practiced corporate and M&A law in the Manhattan offices of one of the leading corporate law firms in the country.
E-Mail: guy@chronodose.com

Bret Berner, PhD

Bret Berner, PhD, will be CTI’s Chief Science Officer, and is one of the world’s foremost authorities on controlled and transdermal drug delivery. Dr. Berner served as Depomed's VP of Product Development since December 1998. Prior to this, Dr. Berner served as VP of Development at Cygnus, Inc. for four years, where he was responsible for project management and timelines, new drug delivery technology formulation, analytical chemistry, and toxicology. From 1984 through 1994, Dr. Berner acted as the director of Basic Pharmaceutics Research at Ciba-Geigy. Prior to 1984, he also held the position of staff scientist at The Procter & Gamble Company. Dr. Berner holds 18 patents, has authored more than 70 publications and edited two books on controlled drug delivery.

George Moonsammy, PhD

George Moonsammy, PhD., will be CTI’s VP of Clinical Affairs, and is a leading transdermal and clinical expert with over 30 years domestic and international expertise in launching pharmaceutical products. Dr. Moonsammy most recently served as Senior Vice President, Clinical, Regulatory, and Medical Affairs at Somerset Pharmaceuticals. In that role, he spearheaded the approval of EMSAM, the first transdermal product to treat depression. Prior to joining Somerset Pharmaceuticals, Dr. Moonsammy spent twenty-nine years at GlaxoSmithKline where he began as a biological research scientist and was promoted to Associate Director - Clinical Research and Development.

Steven Giannos, MS

Steven A. Giannos, MS, CTI’s VP of New Product Development, is a chrono-pharmacological transdermal expert with over 20 years experience in product development and innovative drug delivery technologies. Mr. Giannos’ career includes working on novel transdermal solutions at Novartis (formerly Ciba-Geigy) where he worked with Dr. Bret Berner and other world leading transdermal scientists, Sontra Medical (now Echo Therapeutics, Inc.), and MIT working under Professor Robert Langer. Steven holds 3 patents and has authored a number of book chapters, publications and invited articles on controlled release and drug delivery systems and is active in the Controlled Release Society (CRS) and the American Association of Pharmaceutical Scientists (AAPS).

Dr. Lawrence Blob, MD

Dr. Lawrence Blob, MD, is CTI’s Chief Medical Officer and he successfully sheparded the EMSAM patch approved through the FDA and sold to Bristol Myers Squib, and has a distinguished history of successful entrepreneurial endeavors including founding and selling his own critical care unit and CRO.

Priya Jambhekar, MS

Priya Jambhekar, MS, will be VP of Regulatory Affairs and has with over 18 years of experience in domestic and international regulatory affairs, including 10 years as a department head. Her extensive experience includes establishing regulatory strategy and operational excellence for optimal success during all aspects of pre and post approval phases of Rx, Rx-OTC switch and OTC new and generic drugs. She currently advises Paramount BioSciences.

Mary Lou Zett, PhD

Mary Lou Zett, PhD, is CTI’s Quality Assurance Advisor, and has a distinguished track record of success at the FDA, with over 35 years on the drug side as well as the device side of the FDA.